Proactively manage your pharmacy inventory
Find generic entry opportunities
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Monomeric insulin analog formulations|
|Abstract:||The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.|
|Inventor(s):||De Felippis; Michael R. (Indianapolis, IN)|
|Assignee:||Eli Lilly and Company (Indianapolis, IN)|
|Filing Date:||Jun 01, 1995|
|Claims:||1. A process for preparing an insulin analog-protamine crystal, which comprises: |
combining an aqueous solution of human insulin wherein Pro at position B28 is substituted with Asp, and Lys at position B29 is substituted with Lys or Pro in a hexamer association state, and a protamine solution at a temperature from about 5.degree. C. to about 22.degree. C.;
said aqueous solution comprising from about 0.35 to about 0.9% zinc by weight, human insulin wherein Pro at position B28 is substituted with Asp, and Lys at position B29 is substituted with Lys or Pro, and a phenolic derivative at a pH of about 7.1 to about 7.6;
said protamine solution comprising protamine at a pH of about 7.1 to about 7.6 such that the final concentration of protamine is about 0.27 to about 0.35 mg protamine to 100 IU of insulin analog.
2. The process of claim 1, wherein the process is carried out at a temperature from about 8.degree. C. to about 22.degree. C.
3. The process of claim 2, wherein the process is carried out at a temperature from about 13.degree. C. to about 17.degree. C.
4. The process of claim 3, wherein the process is carried out in less than about 4 mg/mL sodium chloride.
5. The process of claim 4, wherein the insulin is AspB28-human insulin.
6. The process of claim 5, wherein the phenotic derivative is phenol or m-cresol.
7. The process of claim 6, wherein the phenolic derivative is phenol.